Literature DB >> 31365169

ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT.

Chi-Bao Bui1,2, Hoa Kim Le1, Diem My Vu1,3, Kieu-Diem Dinh Truong1, Nhat Manh Nguyen1, Minh Anh Nguyen Ho4, Dinh Quang Truong2.   

Abstract

Aggressive, high-risk neuroblastoma (NB) exhibits an immature differentiation state, profound epigenetic dysregulation and high telomerase activity. It has been suggested that aggressive NB may be treatable by inducing differentiation whereas therapeutic targeting of telomerase is under investigation for multiple cancer types. While epigenetic regulation of the telomerase reverse transcriptase (TERT) promoter has been described in high-risk NB, the exact molecular mechanisms are still not completely understood. Here we used quantitative real-time polymerase chain reaction (PCR), chromatin immunoprecipitation qPCR, quantitative telomeric repeat amplification protocol, and immunoblot techniques to investigate epigenetic regulation of TERT in wild-type and genetically modified NB cell lines. We demonstrated that TERT expression is reduced during 13-cis retinoic acid-induced NB differentiation and that this inversely correlated with increased expression of AT-rich interaction domain 1A (ARID1A), a subunit of the SWItch/sucrose nonfermentable chromatin remodeling complex. We showed that ARID1A directly caused suppression of TERT and was reliant on DNA binding and co-occupancy of the TERT promoter by the SIN3 transcription regulator family member A (SIN3A) repressor complex allowing NB differentiation to proceed. Finally, using data from NB patient cohorts, we reported a significant correlation between low ARID1A expression, elevated expression of TERT, and poorly differentiated, high-risk NB. These results provide insights into a key epigenetic pathway responsible for modulating TERT-driven NB progression, which could represent a target for therapeutic intervention.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer; epigenetic; telomerase

Year:  2019        PMID: 31365169     DOI: 10.1002/mc.23091

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  SWI/SNF chromatin remodeling complex alterations in meningioma.

Authors:  Corey M Gill; Joshua Loewenstern; John W Rutland; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Mary Fowkes; Raj K Shrivastava
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-14       Impact factor: 4.553

2.  A C21-steroidal derivative suppresses T-cell lymphoma in mice by inhibiting SIRT3 via SAP18-SIN3.

Authors:  Babu Gajendran; Krishnapriya M Varier; Wuling Liu; Chunlin Wang; Klarke M Sample; Eldad Zacksenhaus; Cui Juiwei; LieJun Huang; XiaoJiang Hao; Yaacov Ben-David
Journal:  Commun Biol       Date:  2020-12-03

Review 3.  Neuroblastoma and the epigenome.

Authors:  Irfete S Fetahu; Sabine Taschner-Mandl
Journal:  Cancer Metastasis Rev       Date:  2021-01-06       Impact factor: 9.264

4.  Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup.

Authors:  Angela Martinez-Monleon; Hanna Kryh Öberg; Jennie Gaarder; Ana P Berbegall; Niloufar Javanmardi; Anna Djos; Marek Ussowicz; Sabine Taschner-Mandl; Inge M Ambros; Ingrid Øra; Bengt Sandstedt; Klaus Beiske; Ruth Ladenstein; Rosa Noguera; Peter F Ambros; Lena Gordon Murkes; Gustaf Ljungman; Per Kogner; Susanne Fransson; Tommy Martinsson
Journal:  Sci Rep       Date:  2022-07-20       Impact factor: 4.996

5.  ARID1A-dependent maintenance of H3.3 is required for repressive CHD4-ZMYND8 chromatin interactions at super-enhancers.

Authors:  Jake J Reske; Mike R Wilson; Brooke Armistead; Shannon Harkins; Cristina Perez; Joel Hrit; Marie Adams; Scott B Rothbart; Stacey A Missmer; Asgerally T Fazleabas; Ronald L Chandler
Journal:  BMC Biol       Date:  2022-09-25       Impact factor: 7.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.